Note: ONLY CANDIDATES WILLING TO MOVE TO CHINA SHOULD APPLY

Location: Zhejiang Province. Hangzhou and the surrounding areas

Project Name: Development of iodine contrast agent technology and research on innovative generic drugs

Client- Zhejiang starry pharmaceutical Co. Ltd.

Industry- Biological medicine

Unit Information- client information, main areas of activity, project background, etc.-

The company was established in 1997, is engaged in the research and development, production, sales of x-ct non-ionic iodine-contrast agent series and quinolones series API and intermediate national high-tech enterprises. In March 2016, staili pharmaceuticals successfully entered China's a-share market on the Shanghai stock exchange (stock code 603520). The company is currently the largest manufacturer of non-ionic contrast agent API with the largest production capacity in China. It is also one of the companies with the most abundant product lines of X-ray CT contrast agent API in China. The company has stable product quality and has been certified by many developed countries. The company has zhejiang pharmaceutical research institute, zhejiang enterprise technology center, zhejiang non-ionic contrast agent high-tech research center and zhejiang postdoctoral workstation for r & d and other technical platforms. The r & d center has more than 100 million yuan of instruments and equipment, including 20 synthesis laboratories, 6 analysis laboratories, and 3 100,000-level pilot test amplification workshops, with a total r & d area of more than 5,000 square meters

Nature of Activity Requested for Experts- Project description, assignment target, etc.-

Description :

The products with industrialization capacity are iohexanol API, iohopanol API, iofortanol API, ioproramine API, iohexanol API and so on. The company's leading product iohexanol obtained European Union CEP certificate and Japanese landing certificate. The production capacity and output of iohexanol API of our company are the first in China. Among them, ioppanol obtained eu CEP certificate and Japanese landing certificate; The company's sales volume of ioxanol in 2019 ranked the first in China

Issues to solve :

- Lead the group's drug research and development work, study the future product layout, formulate five-year development plan;

- Lead the development of new products, lead the research group to carry out special projects;

- Responsible for the group's overseas business expansion, the opening up of resource channels, and the increase of international influence 

Statistics & Data :

Break through the bottleneck of generic drug technology, reduce the production cost by more than 10% and increase the yield by 5-10%;

Launch 1-2 generic drugs with high added value and complete FDA system certification;

Increased the market share of the company's contrast agent products in European and American countries by 20%;

Expert qualification required- Professional, degree- language, experience, etc- and assignment target date, duration and location-

Have more than 10 years' experience in r&d team management, and priority will be given to r&d leaders or chief scientists of companies like Mallinckrodt, Bracco, GE, Bayer, Guerbet, Pfizer, Roche, Novartis- MSD- Sanofi.Preference will be given to personnel with related working background in chemical generic drugs, who can understand Chinese;Able to adapt to work and life in China, working in China for more than 9 months every year;

This job opening was posted long time back. It may not be active. Nor was it removed by the recruiter. Please use your discretion.